Protagonist Therapeutics launches USD 300 million share buyback program

Cash, cash equivalents and marketable securities totaled USD 849.5 million as of June 30, 2026, excluding expected Takeda payments.

The program's size and timing will depend on market conditions, share price, incoming collaboration cash flows and capital allocation priorities.

Repurchases may occur in the open market, including under a Rule 10b5-1 trading plan. The program can also be paused or ended.

Protagonist Therapeutics launched a share repurchase program for up to USD 300 million of outstanding common stock.

Funding is planned from cash, cash equivalents, marketable securities, royalties and collaboration payments tied to its Takeda and Johnson & Johnson deals.